News Medical on MSN5d
Gene therapy breakthrough offers hope for severe Dravet syndrome cases
AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
GlobalData on MSN4d
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...
FierceBiotech9d
Encoded lays off 29% of staff to fund Dravet syndrome gene therapy trial
Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage ...
FierceBiotech5d
Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline
Existing treatments for Dravet include Jazz Pharmaceuticals’ Epidiolex and UCB’s Fintepla, but none of the approved products address the underlying genetic cause of the syndrome. Similarly ...
Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration
Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of ...
Yahoo Finance4d
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...